Bifogade filer
PDF
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Spotlight DK |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.
- The increase in share capital and number of shares arising from the rights issue of shares in May 2025 has now been registred with Danish Business Authority.
- It is expected that the first day of trading of the new shares from the rights issue will be 6 June 2025 and the estimated date for conversion to ordinary shares is 10 June 2025.
21 May 2025, Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announced the outcome of the Company's rights issue of shares, which had a subscription period running between 2 May and 16 May 2025 (the "Rights Issue").
Registration of the new shares from the Rights Issue has now been completed with Danish Business Authority. In the Rights Issue, a total of 23,737,362 shares were subscribed for including activated guarantee subscription. As a result of subscription in the Rights Issue, the Company's share capital was increased by DKK 1,186,868.10. After registration of the Rights Issue, Curasight's share capital now amounts to DKK 2,244,312.10, corresponding to 44,886,242 shares. The quota value thus amounts to DKK 0.05 per share.
It is expected that the first day of trading of the new shares from the rights issue will be 6 June 2025 and the estimated date for conversion to ordinary shares is 10 June 2025.
Advisors
Sedermera Corporate Finance AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue. DLA Piper is the Company's legal advisor. Danske Bank A/S is the settlement agent.